Introduction
============

It is well established that cell populations in the adult CNS exist which are able to give rise to cells of all major cell lineages including neurons, oligodendrocytes and astrocytes (Alvarez-Buylla and Lois, [@B4]; Horner *et al.*, [@B29]; Nunes *et al.*, [@B51]). Although the ability of these cells to replace lost neurons is relatively poor their ability to replace oligodendrocytes (and hence remyelinate demyelinated axons) can be very efficient in both experimental models and sometimes in clinical disease (Patrikios *et al.*, [@B55]; Patani *et al.*, [@B54]; Blakemore and Franklin, [@B11]). Remyelination in the CNS is mediated by a multipotent adult stem/precursor cell population traditionally referred to as oligodendrocyte precursor cells (OPCs) (ffrench-Constant and Raff, [@B20]; Wolswijk and Noble, [@B85]; Gensert and Goldman, [@B25]; Carroll *et al.*, [@B13]; Sim *et al.*, [@B64]). Although remyelination can be efficient it often fails in clinical disease for reasons that are not fully understood (Franklin, [@B22]). The chronic demyelination that follows is associated with axonal loss, so providing a possible mechanism for progressive disability in patients suffering from diseases in which chronic demyelination occurs of which the most important is multiple sclerosis. Several lines of evidence both experimental (Woodruff *et al.*, [@B86]; Foote and Blakemore, [@B21]) and clinical (Wolswijk, [@B83], [@B84]; Chang *et al.*, [@B15]; Totoiu and Keirstead, [@B73]; Kuhlmann *et al.*, [@B39]) point to the failure of OPC differentiation as a major cause of remyelination failure. Indeed, regulation of OPC differentiation in remyelination represents an attractive model for the more general stem cell medicine challenge of inducing differentiation of repair cells from adult neural stem/precursor cells.

A possible explanation for the failure of OPC differentiation in multiple sclerosis is the presence of inhibitors within demyelinated lesions. A number of potential inhibitors have been proposed including axonal PSA-NCAM in chronically demyelinated lesions (Charles *et al.*, [@B16]), astrocytic hyaluronan (Back *et al.*, [@B7]) and notch-jagged (John *et al.*, [@B32]) signalling, although these are not always supported by functional studies in animals models (Stidworthy *et al.*, [@B67]). We have previously shown that myelin debris accumulating in lesions as a result of demyelination exerts a powerful inhibitory effect on OPC differentiation unless it is cleared by phagocytes (Kotter *et al.*, [@B36]). With ageing, the efficiency of myelin debris removal decreases (Ibanez *et al.*, [@B30]) and this may contribute to the impairment in OPC differentiation that underlies the age-associated decline in remyelination efficiency (Sim *et al.*, [@B64]; Woodruff *et al.*, [@B86]).

In this study, we identified potential protein inhibitors by column-chromatography based purification of inhibitory fractions followed by 3D gel electrophoresis and Nano-HPLC-ESI-Q-TOF mass spectrometry. We explored the cell intrinsic mechanisms by which myelin inhibits OPC differentiation in order to identify pathways that can be pharmacologically modulated and hence used as potential remyelination-enhancing therapies. We address the hypothesis that myelin-mediated inhibition of OPC differentiation is mediated by (i) Src-family (Fyn-1)--RhoA-ROCK-II signalling or (ii) protein kinase C (PKC) pathway signalling. By assessing the activation of key molecules of both pathways, we provide evidence of a direct involvement of Src family kinase Fyn and RhoA in mediating the inhibitory effects as well as a modulation of PKC signalling. Our results demonstrate that inhibition of either ROCK-II or PKC is able to induce OPCs differentiation in the presence of myelin thus providing a mechanism which could be of significant therapeutic value.

Materials and methods
=====================

Preparation and purification of OPC
-----------------------------------

Primary cultures of OPCs were isolated from P0 to P2 neonatal Sprague-Dawley rat forebrains following a standard protocol (McCarthy and de Vellis, [@B45]) that we have adapted for our purposes (Syed *et al.*, [@B68]). In brief, hemispheres were stripped free of meninges, after a digestion step the cells were plated into cell culture flasks and mixed glia cultures were grown for ∼10 days in DMEM medium supplemented with 10% FCS at 37°C and 7.5% CO~2~. To remove the loosely attached microglia, the flasks were shaken for 1 h at 260 r.p.m. on an orbital shaker before being shaken at 260 r.p.m. overnight to dislodge the loosely attached oligodendrocyte precursors. OPCs were further purified from contaminating microglia by a differential adhesion step. Subsequently, OPCs were plated onto polylysine (PLL)-coated or substrate coated dishes. To maintain cells at an early precursor stage PDGF-AA (Pepro Tech, Rocky Hill, NJ, USA) and FGF (Pepro Tech) were added (10 ng/ml) to SATOs medium. To induce differentiation, cells were incubated in SATOs medium supplemented with 0.5% FCS. The purity of each culture was monitored following OPC purification by immunocytochemistry and only cultures with \>94% purity were used. Minor contaminations of microglia, that can be detected by isolectin staining and which amount to 4--5% of the cells, astrocytes (detectable by GFAP) and fibroblasts with distinct morphology and which account for ∼1--2% of the cells, were present in the cultures.

Preparation of myelin membrane substrates and myelin protein extracts
---------------------------------------------------------------------

Myelin was purified by two rounds of discontinuous density gradient centrifugation and osmotic disintegration (Norton and Poduslo, [@B50]). Total brains of young Sprague-Dawley rats were homogenized mechanically in ice-cold 0.32 M sucrose using a mechanical blender (Ultra-Turrax; IKA, T18 basic, Germany). Sucrose was dissolved in sterile 2.5 mM Tris/HCl, pH 7.0, to form 0.25, 0.32 and 0.88 M solutions. The homogenized brains were diluted to a final 0.25 M sucrose solution and pelleted in an ultra-centrifuge (55 000 *g*, 4°C, 15 min). The pellet was re-suspended in 0.88 M sucrose solution and overlaid with 0.25 M sucrose. After an ultracentrifugation step (100 000 *g*, 4°C, 1 h), the interface was collected and washed in 30 ml of distilled H~2~O (55 000 *g*, 4°C, 10 min). The pellet was re-suspended in dH~2~O and incubated for 60 min on ice for osmotic disintegration. After centrifugation (55 000 *g*, 4°C, 10 min), the flotation step was repeated. The interface was collected and washed twice in dH~2~O (55 000 *g*, 4°C, 10 min), and the pellet was stored at --80°C until isolation of myelin protein extracts (MPEs).

To prepare MPE the pellets were resuspended in 1% *N*-octyl β-[d]{.smallcaps}-glucopyranoside, 0.2 M Sodiumphosphate pH 6.8, 0.1 M Na~2~SO~4~ and 1 mM EDTA and incubated at 23°C for 2 h. Following an ultracentrifugation step (100 000 *g*, 18°C, 30 min) the supernatants were collected and stored at --20°C until further usage (Kotter *et al.*, [@B36]; Syed *et al.*, [@B68]).

Isolation of liver membrane fractions
-------------------------------------

Sucrose (0.85 and 1.23 M) in 2.5 mM Tris/HCl was prepared as outlined above. The liver of a young adult Sprague-Dawley rat was extracted and homogenized in 0.85 M sucrose (using an Ultra-Turrax). The homogenate was layered onto a 1.23 M sucrose solution. After centrifugation (100 000 *g*, 4°C, 1 h) the interface was collected and washed in dH~2~O (55 000 *g*, 4°C, 10 min). Finally, the pellet was resuspended in an equal volume of 1× PBS containing 1% octyglucoside and 1 mM EDTA. After incubation at 25°C for 2 h in a shaker the sample was ultracentrifuged at 100 000 *g* for 30 min and finally, the supernatant was stored at --20°C until further use. The protein concentration was estimated by BCA assay (Pierce, Rockford, IL, USA) (Kotter *et al.*, [@B36]).

Chromatography column based separation of inhibitory myelin protein fractions
-----------------------------------------------------------------------------

About 50 ml of the MPE (∼1 mg/ml) were filtered through a 0.22 µ Millipore membrane filter. The filtrate was desalted and concentrated using Amicon ultrafiltration cell (Millipore, Billerica, MA, USA; membrane diameter 44.5 mm; cut off 10 000 Da) with 50 mM sodium acetate (pH4). This step was repeated three times to ensure that the sample was maximally desalted. The concentrated and desalted lysate was subsequently loaded on a CM column (Econo-Pac CM cartridges, 1 ml, Biorad, Hercules, CA, USA). Column chromatography was performed using an FPLC System with a built in detector (Pharmacia Fine Chemicals, GE Healthcare, Bucks. UK). The injection volume was 10 ml; 50 mM sodium acetate buffer containing 1% octlyglucoside (mobile phase A) was used as washing buffer and 1 M NaCl containing 1% octylglucoside (mobile phase B) was used as elution buffer. The following chromatographic gradients were applied: 0% B for 15 min, 0--70% B, hold with 70% B for 10 min followed by a wash with A for 10 min. The flow rate used was 2 ml/min, the fraction size 1 ml/min and sensitivity of the detector was 1 U at a wavelength of 280 nm.

The non-binding fractions and the binding fractions were pooled together separately and assessed for inhibitory activity on OPC differentiation using the *in vitro* substrate assay outlined below. Repeat experiments demonstrated that the inhibitory effects on OPC differentiation were associated with the nonbinding fraction of the CM column.

To further eliminate proteins with non-inhibitory activity, the inhibitory non-binding fraction was concentrated and the buffer exchanged to a 0.1 M Tris--Cl buffer containing 1% octlylglucoside (pH 8). The concentrate was subsequently loaded on an anion exchange EconoPac High Q cartridge (1 ml; Bio-Rad) and coupled to the FPLC system (GE Healthcare UK Ltd, Little Chalfont, Buckinghamshire, UK). 0.1 M Tris--Cl containing 1% octylglucoside was used as washing buffer (Mobile phase A). The binding fraction was eluted using 1 M NaCl in 0.1 M Tris--Cl containing 1% octylglucoside (Mobile Phase B). The injection volume was 10 ml. The reaction conditions were as follows: 0% B in 5 min and 0--100% B in 10 min, 100% B for 10 min and washing with A for 5 min. The flow rate was maintained at 2 ml/min at 25°C. The detection wavelength was 280 nm and sensitivity set at 1 U.

The resulting binding and non-binding fractions were again pooled separately. When tested for their inhibitory effects the inhibitory activity was associated with the binding fraction. The pooled binding fractions were further concentrated and the buffer exchanged to a buffer composed of 250 mM 6-aminocaproic acid, 25 mM Bis--Tris, pH 7.0 using Amicon ultra centrifugal filter devices.

One dimensional electrophoresis: BN-PAGE
----------------------------------------

60 µl of purified inhibitory myelin protein fractions (∼2 µg/µl) was added to 10 µl of G250 solution \[5% (w/v) Coomassie G250 in 10 mM 6-aminocaproic acid\] and loaded onto the gel. BN-PAGE (Wittig *et al.*, [@B81]) was performed in a PROTEAN II xi Cell (BioRad, Germany) using a 4% stacking and a 5--13% separating gel. The gel buffer contained 250 mM 6-aminocaproic acid, 25 mM Bis-Tris, pH 7.0; the cathode buffer 50 mM Tricine, 15 mM Bis-Tris, 0.05% (w/v) Coomassie G250, pH 7.0; and the anode buffer 50 mM Bis-Tris, pH 7.0. For electrophoresis, the voltage was set to 70 V for 2 h, and was increased to 250 V (10 mA/gel) until the dye front reached the bottom of the gel. BN-PAGE gels were cut into small pieces of ∼1--3 cm depending on the intensity of protein bands for the BN/SDS/SDS--PAGE three dimensional electrophoresis (3DE).

Three dimensional electrophoresis: BN/SDS/SDS--PAGE
---------------------------------------------------

The experimental procedures and advantages of BN/SDS/SDS--PAGE (3DE) are summarized in Kang *et al.* ([@B34]). Briefly, 1--3 cm gel pieces from BN-PAGE were soaked for 2 h in a solution of 1% (w/v) SDS and 1% (v/v) 2-mercaptoethanol. Gel pieces were then rinsed twice with SDS--PAGE electrophoresis buffer \[25 mM Tris--HCl, 192 mM glycine and 0.1% (w/v) SDS; pH 8.3\], then the gel pieces were placed onto the wells. 2DE-SDS--PAGE was performed in PROTEAN II xi Cell using a 4% stacking and a 6--13% separating gel for BN/SDS--PAGE (2DE). Electrophoresis was carried out at 25°C with an initial current of 70 V (during the first hour). The voltage was then set to 100 V for the next 12 h (overnight), and increased to 200 V until the bromophenol blue marker moved 17 cm from the top of separation gel.

2DE gels were cut again into lanes and gel strips from each lane were soaked for 20 min in a solution of 1% (w/v) SDS and 1% (v/v) 2-mercaptoethanol. Gel strips were then rinsed twice with SDS--PAGE electrophoresis buffer (25 mM Tris--HCl, 192 mM glycine and 0.1% (w/v) SDS; pH 8.3), and were placed onto the wells of another gel (3DE). SDS--PAGE was performed in PROTEAN II xi Cell using a 4% stacking and a 7.5--17% separating gel. Electrophoresis was carried out at 25°C with an initial current of 70 V (during the first hour). Then, the voltage was set to 100 V for the next 12 h (overnight), and increased to 200 V until the dye front reached the bottom of the gel. Colloidal Coomassie blue staining was used for visualization.

In-gel digestion of purified myelin fraction with trypsin
---------------------------------------------------------

The gel pieces of interest were cut into small pieces to increase surface and collected in a 0.6 ml tube. They were initially washed with 50 mM ammonium bicarbonate and then twice with 50% 50 mM ammonium bicarbonate/50% acetonitrile for 30 min with occasional vortexing. The washing solution was discarded at the end of each step. 100 microlitre of 100% acetonitrile was added to each tube to cover the gel piece followed by incubation for at least 5 min. The gel pieces were dried completely in a Speedvac Concentrator 5301 (Eppendorf, Germany). Cysteines were reduced with a 10 mM dithiothreitol solution in 0.1 M ammonium bicarbonate pH 8.6 for 60 min at 56°C. The same volume of a 55 mM solution of iodoacetamide in 0.1 M ammonium bicarbonate buffer pH 8.6 was added and incubated in darkness for 45 min at 25°C to alkylate cysteine residues. The reduction/alkylation solutions were replaced by 50 mM ammonium bicarbonate buffer for 10 min. Gel pieces were washed and dried in acetonitrile followed by Speedvac concentration.

The dried gel pieces were re-swollen with 12.5 ng/µl trypsin (Promega, WI, USA) solution buffered in 25 mM ammonium bicarbonate. They were incubated for 16 h (overnight) at 37°C. Supernatants were transferred to new 0.6 ml tubes, and gel pieces were extracted again with 50 µl of 0.5% formic acid/20% acetonitrile for 15 min in a sonication bath. This step was performed twice. Samples in extraction buffer were pooled in a 0.6 ml tube and evaporated in a Speedvac. The volume was reduced to ∼10 µl and 10 µl water was added.

Protein identification with Nano-HPLC-ESI-Q-TOF mass spectrometry
-----------------------------------------------------------------

LC-ESI-MS/MS analyses were carried out with the UltiMate 3000 system (Dionex Corporation, Sunnyvale, CA, USA) interfaced to the QSTAR Pulsar mass spectrometer (Applied Biosystems, Foster City, CA, USA). A nanoflow HPLC equipped with a reversed phase PepMap C-18 analytic column (75 µm × 150 mm) was used. Chromatography was performed using a mixture of two solutions, A (0.1% formic acid in water) and B (80% acetonitrile/0.85% formic acid in water), with a flow rate of 300 nl/min. First a linear gradient between 4% and 60% B was run over 45 min, then 90% B was used for 5 min and 0% B for 25 min. Peptide spectra were recorded over the mass range of *m/z* 350--1300, and MS/MS spectra were recorded under information dependent data acquisition (IDA) over the mass range of *m/z* 50--1300. One peptide spectrum was recorded followed by three MS/MS spectra on the QSTAR Pulsar instrument; the accumulation time was 1 s for peptide spectra and 2 s for MS/MS spectra. The collision energy was set automatically according to the mass and charge state of the peptides chosen for fragmentation. Doubly or triply charged peptides were chosen for MS/MS experiments due to their good fragmentation characteristics. MS/MS spectra were interpreted by the MASCOT software (mascot.dll 1.6b21; Matrix Science, London, UK) in Analyst QS 1.1 (Applied Biosystems). Searches were done by using the MASCOT 2.1 (Matrix Science, London, UK) against Swissprot 53.3 and MSDB 20051115 database for protein identification. Searching parameters were set as follows: enzyme selected as trypsin with a maximum of two missing cleavage sites, species limited to mouse, a mass tolerance of 500 ppm for peptide tolerance, 0.2 Da for MS/MS tolerance, fixed modification of carbamidomethyl (C) and variable modification of methionine oxidation and phosphorylation (Tyr, Thr and Ser).

Immunocytochemistry
-------------------

The pooled OPCs harvested as outlined above were seeded at a density of 20 000 cells per well into PLL-coated eight-well chamber slides. Cells were differentiated for 48 h and subsequently fixed with 4% paraformaldehyde in PBS, permeabilized and blocked with 0.3% Triton X-100 and 10% NGS. To assess the differentiation state of OPCs the cells were incubated with O4 antibody (1:100; Millipore Corporation, Billerica, MA, USA) for 1 h in the presence of 0.1% Triton X-100 and 2% NGS, washed, and incubated for another 1 h with the appropriate fluorescent secondary antibody (Cy3-conjugated antibody 1:100; Jackson Immuno Research, Suffolk, UK) and the nuclei were stained using DAPI (Robinson and Miller, [@B59]; Syed *et al.*, [@B68]). It is important to note that permeabilization of cells results in a punctate representation of the extracellular antigen O4 (Reynolds and Weiss, [@B57]; Weiss *et al.*, [@B79]; Syed *et al.*, [@B68]). Under an Olympus X51 fluorescent microscope using a triple-filter we determined the percentage of O4-positive cells in relation to \>100 DAPI-stained nuclei in randomly selected eye fields for each experimental condition.

To establish the purity of our OPC cultures immunocytochemistry for A2B5 (1:100; Millipore Corporation, Billerica, MA, USA) was performed according to the same principles and the percentage of A2B5+ cells to \>100 DAPI-stained nuclei in randomly selected eye fields was determined. Only cell cultures with \>94% A2B5+ cells were used for our study. To assess the morphological phenotype of OPCs, A2B5+ cells were categorized according to the following criteria: stage I: mono/bipolar; stage II: multipolar, primary branched; stage III: multipolar, secondary branched; stage IV: secondary branched cells with membranous processes.

qPCR for myelin basic protein versus β-2-microglobulin
------------------------------------------------------

Total RNA of OPCs grown on PLL control or MPE substrates with various concentrations (0.4 µg MPE, 4 µg MPE and 40 µg MPE) was harvested after the cells were differentiated for 3 days using RNeasy Mini Kit (Quiagen, Hilden, Germany) according to the manufacturer\'s instruction.

First strand cDNA synthesis kit for RT--PCR (Roche Applied Science, Vienna, Austria) was used for reverse transcription of 500 ng RNA (each sample) according to the manufacturer\'s instructions.

q-PCR was performed using Taqman gene expression assays for myelin basic protein (MBP) (ABI, Foster City, CA, USA, Rn 00566745_M1) and β-2-microglobulin (β2-MG) (ABI, Rn 00560865). Three independent experiments were conducted and all reactions were performed in triplicate on a 7500 Fast Real-Time PCR System. Semi-quantitative mRNA expression levels were calculated with the 7500 Fast System Software (ABI, Foster City, CA).

Pharmacological inhibition of ROCK-II and PKC
---------------------------------------------

To examine whether ROCK-II and PKC signal transduction is implicated in the myelin mediated differentiation block, pharmacological inhibitors were added to the culture medium immediately after cell seeding. The selective PKC-inhibitor Gö6976 specific for PKC-α and PKC-β (12-(2-cyanoethyl)-6,7,12,13-tetrahydro-13-methyl-5-oxo-5H-indolo\[2,3-a\]pyrrollo\[3,4-c\]carbazole; CAS-number: 136194-77-9) and BIM (Ro 31-8220, Bisindolylmaleimide IX; CAS-number: 125314-64-9) selectively affecting all PKC isoforms were used to block PKC-signalling. To inhibit ROCK-II, an orally available drug currently evaluated for the treatment of vascular disease named Fasudil (HA-1077 dihydrochloride; 1-(5-Isoquinolinesulfonyl)-1H-hexahydro-1,4-diazepine 2 HCl; CAS-number: 103745-39-7) was used with the potential of interfering with Rho kinase, PRK2, MSK1, PKA, PKG, S6K1, MAPKAP-K1b, MLCK and CaMKII signalling. Gö6976 and BIM were solubilized in DMSO. OPCs plated on different substrates were differentiated for 48 h and subsequently fixed for immunocytochemistry. To quantitate differentiation, the ratio of O4 positive cells and the number of Hoechst-positive nuclei was determined by cell counts using an Olympus IX 51 fluorescence microscope. A minimum of 200 cells were counted for each experiment and a minimum of three independent experiments were conducted.

siRNA-based downregulation of RhoA and PKC-α
--------------------------------------------

Ten days after plating mixed glial cultures were transfected with siRNA for PKC-α, RhoA, negative control siRNA and Cy^TM3^ labelled negative control (Applied Biosystems) using Lipofectamine 2000 (Invitrogen, Paisley, UK) at a concentration of 100 nM according to the manufacturer\'s protocol. Twenty-four hours later OPCs were harvested as outlined above. To determine the knock-down efficiency of the targeted genes Western blot analyses were performed for RhoA (Millipore Corporation) or PKC-α (Cell Signalling, Danvers, MA, USA). OPC differentiation was assessed as outlined above 48 h after plating cells onto the experimental substrates; at least three independent experiments were conducted for each condition.

TUNEL assay
-----------

Fragmented DNA was detected by incorporation of biotinylated nucleotides at the 3′-OH DNA ends using terminal deoxynucleotidyl transferase recombinant (rTdT) enzyme according to the manufacturer\'s instruction (Promega, Madison, WI, USA). Stained cells were visualized by light microscopy and the percentage of apoptotic nuclei was determined.

Western blot analysis
---------------------

OPCs differentiated for 24 h and 9 days on PLL were lysed in a buffer containing 10 mM Tris, pH 7.4, 100 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1 mM NaF, 20 mM Na~4~P~2~O~7~, 2 mM Na~3~VO~4~, 0.1% SDS, 0.5% Sodium Deoxcholate, 1%Triton-X100, 10% Glycerol, 1 mM PMSF, 60 µg/ml Aprotinin, 10 µg/ml Leupeptin, 1 µg/ml Pepstatin. After high speed centrifugation, protein concentration was measured using BCA^TM^ protein assay (Pierce) and 15 µg were loaded on SDS--PAGE for separation. Western blot was conducted using a Multiphor II Electrophoresis System (GE Healthcare UK Ltd) at 200 mA for 1.30 h. After blocking with 5% BSA in TBS-T (0.1% Triton X 100 in TBS) for 1 h at room temperature the blots were incubated with antibodies against ROCK II/ROKα (BD Biosciences, San Jose, CA, USA), RhoA (Millipore Corporation) or PKC-α (Cell Signalling) antibodies over night (4°C). Following incubation with horseradish-peroxidase conjugated secondary antibody (GE Healthcare UK Ltd) for 1 h the immunoreactive bands were detected by ECL^TM^ chemiluminescence (GE Healthcare UK Ltd) reagent on a film.

To confirm the presence of proteins identified by MS analysis in the purified inhibitory fractions, 10 µg of protein was separated using 12% Novex gel (Invitrogen). MPE was used as positive control and protein extracts of liver membrane preparation as negative control. Following SDS--PAGE, the protein was then transferred to PVDF membrane using an Xcell II Blot Module (Invitrogen). After blocking with 5% BSA in TBS-T (0.1% Triton X 100 in TBS) for 1 h at room temperature it was probed overnight at 4°C with the following antibodies: myelin-associated glycoprotein (MAG) (Millipore Corporation), PLP (kindly provided by Lees MB), MBP (DAKO). Following a wash step the membranes were incubated with the appropriate horseradish-peroxidase conjugated secondary antibody (GE Healthcare UK Ltd) for 1 h. The immunoreactive bands were detected by ECL^TM^ chemiluminescence (GE Healthcare UK Ltd) reagent on a film.

Evaluation of Fyn activation
----------------------------

Cells were washed twice with ice cold PBS before being lysed in 10 mM Tris, 100 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1 mM NaF, 2 mM Na~3~VO~4~, 0.1% Triton, 10% Glycerol, 1 mM PMSF, 0.5% Na-Deoxycholate, 20 mM Na~4~P~2~O~7~ and protease inhibitor (Roche). Cell lysates were centrifuged (1 h, 3200 rpm, 4°C) and the protein concentration was estimated by BCA^TM^ assay (Pierce). The lysates were pre-cleared with A/G Plus Agarose beads (Santa Cruz, CA, USA) for 30 min at 4°C and incubated with total Fyn antibody (Santa Cruz) for 2 h in a rotary mixer following addition of A/G Plus Agarose beads for overnight incubation. Before performing SDS--PAGE and Western blot the immune complexes were washed extensively with NP-40 buffer and PBS. The precipitates were re-suspended in sample buffer, heated to 95°C for 5 min, and subjected to SDS--PAGE. Proteins were transferred to a PVDF membrane, blocked with bovine serum albumin and incubated with Y-418-phospho-Src (Biosource) antibody. Finally a horseradish-peroxidase conjugated secondary antibody was added and detected by ECL^TM^ chemiluminescence (GE Healthcare UK Ltd) reagent on film. The optical density of the bands was estimated with NIH-Image J (free download at <http://rsb.info.nih.gov/ij/>) on digitized images.

RhoA GTPase activity assay
--------------------------

For the detection of active RhoA, OPCs were lysed (125 mM HEPES, pH 7.5, 750 mM NaCl, 5% Igepal CA-630, 50 mM MgCl~2~, 5 mM EDTA, 10% Glycerol, 25 mM NaF, 1 mM Na~3~VO~4~) according to the manufacturer\'s instructions (Millipore Corporation) and active GTP-Rho was precipitated by the use of beads specific for the GST-binding domain (RBD) of rhotekin. After removing cell debris the lysates were incubated with Rho Assay Reagent Slurry, which specifically binds Rho-GTP and not Rho-GDP (30 min, 4°C). Beads were then washed with Mg^2+^ lysis/wash buffer and bound material was eluted with 25 µl 2× Laemmli sample buffer, boiled for 5 min, resolved by SDS--PAGE and immunoblotted using mouse anti-RhoA antibody (3 µg/ml). Peroxidase-conjugated anti-mouse IgGs (GE Healthcare UK Ltd) were used as secondary antibodies. Immunoreactive proteins were visualized using ECL^TM^ detection system (GE Healthcare UK Ltd). Densitometric analysis was performed using NIH-Image J software.

Statistical analysis
--------------------

For all studies at least three independent experiments (*n* as detailed in results) were conducted and statistically assessed using Graph Pad Prism software (Graph Pad, San Diego, CA). To test the concentration dependent inhibition of OPC differentiation on MPE and the effect of various concentrations of pharmacological inhibitors one way ANOVA followed by Dunett\'s multiple comparison test was used. ROD values from Western blot following immunoprecipitation or pull-down assay were compared with Student-*t*-test.

Results
=======

Soluble myelin molecules inhibit the differentiation of OPCs
------------------------------------------------------------

To establish an *in vitro* assay for assessing the effects of myelin on OPC differentiation we adapted an approach previously reported by Robinson and Miller and plated neonatal OPCs on myelin substrates produced by incubation of myelin preparations on poly-[l]{.smallcaps}-lysine covered culture dishes (Robinson and Miller, [@B59]). The differentiation of oligodendrocyte lineage cells (OLCs) *in vitro* is characterized by distinct morphological and immunological features. Antibodies against O4 identify late OPCs by reacting with a sulphated glycolipid antigen named POA (Proligodendrocyte Antigen), while the same antibody also recognizes terminally differentiated OLCs by reacting with sulphated galactosylcerebroside (Bansal *et al.*, [@B8]). The differentiation block mediated by presence of myelin is manifested as a reduction in O4-expression by OPCs (Robinson and Miller, [@B59]). In a previous study we showed that MPEs prepared with *n*-octyl-glycoside induce a concentration-dependent inhibition of differentiation in OPCs cultured in differentiation medium for 48 h similar to that observed with crude myelin membrane preparations (Syed *et al.*, [@B68]). The inhibition of OPC differentiation is not only reflected by a reduction of O4 expression but also by a corresponding downregulation of mRNA expression for MBP, a late marker of mature oligodendrocytes, as assessed by qPCR ([Fig. 1](#F1){ref-type="fig"}; *n* = 3). The presence of myelin was associated with a reduction in the complexity of OPC processes resulting in an increase of early OPC phenotypes with bipolar (stage I) morphology or primary branches (stage II) and a consecutive reduction of OPCs with secondary branched or membranous processes (stage III/IV) ([Fig. 6](#F6){ref-type="fig"}) (one-way ANOVA *P* \< 0.0001). We also confirmed previous data (Robinson and Miller, [@B59]) demonstrating that no changes occurred in the rate of cell proliferation as assessed by BrdU staining (no BrdU-positive cells were detected in the experimental groups) or apoptosis assessed by TUNEL assay, indicating that differences in the proportion of O4-positive cells reflect changes of cell differentiation and that these were not caused by an increase of OPC proliferation or differences in the rate of apoptosis ([Supplementary Fig. 1](http://brain.oxfordjournals.org/cgi/content/full/awn334/DC1)). Fig. 1OPCs plated on MPEs (protein/cm^2^) display a concentration dependent down-regulation of relative MBP mRNA expression as assessed by qPCR after 3d culture in differentiation medium (for this and subsequent figures: MPE: myelin protein extract; error bars: SEM).

Purification of inhibitory myelin fractions and proteomic analysis
------------------------------------------------------------------

The myelin proteins responsible for the inhibition of OPC differentiation are unknown. The most prominent myelin associated inhibitors (MAI) NogoA, MAG and Omgp do not affect OPC differentiation (Syed *et al.*, [@B68]). To identify potential candidates we developed a column-chromatography fractionation protocol. In the first step MPE was submitted to a CM-column, and the resulting fractions tested by plating OPCs on the eluates. The fraction carrying inhibitory activity was then submitted to a second purification step using an ion exchange column (HighQ). The eluates obtained were tested in the same manner and the final inhibitory fraction was used for proteomic analysis.
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Myelin impairs activation of the Src family tyrosine kinase Fyn-1
-----------------------------------------------------------------

To investigate the basis of the myelin mediated inhibition of OPC differentiation we examined the activation of Src family tyrosine kinase Fyn-1. Several lines of evidence implicate an important role for Fyn-1 in the formation of myelin sheaths: first, the myelin content found in brains of fyn-deficient mice is reduced, and second, Fyn-1 can be co-immuno-precipitated from brain lysates with antibodies to MAG (Umemori *et al.*, [@B74]). More recent data suggest that activation of Fyn-1 is one of the earliest events triggered in differentiating OPCs and that Fyn-1 tyrosine kinase regulates process extension and myelin sheath formation (Osterhout *et al.*, [@B53]; Colognato *et al.*, [@B18]).

Protein extracts from OPCs plated on MPE cultured in differentiation medium for 24 h were compared with protein extracts from OPCs plated on control substrates under the same conditions by immuno-precipitation with anti-Fyn-1 and immunoblotting with anti-Src Y-418, to detect phosphorylation at the activation site of Fyn-1. The results demonstrated a clear impairment of Fyn-1 activation in cells plated on MPE (*n* = 4; *t*-test *P* = 0.0003; [Fig. 2](#F2){ref-type="fig"}A and B). In OPCs plated on control substrate phosphorylation of Fyn-1 increased over time as previously reported (Osterhout *et al.*, [@B53]). Fig. 2(**A**) Myelin inhibitors impair Fyn-1/Y-418 phosphorylation in OPCs, (**B**) immunoblot following anti-Fyn-1-immunoprecipitation and loading control. (**C**) Myelin inhibitors also induce activation of RhoA. (**D**) Autoradiograph of Rho assay (MPE: 40 µg/cm^2^; PLL: poly-[l]{.smallcaps}-lysine; incubation in differentiation medium for 24 h).

Myelin molecules mediate inhibitory signals via activation of RhoA
------------------------------------------------------------------

Fyn-1 kinase regulates the activity of the small GTPase RhoA (Colognato *et al.*, [@B18]), which, along with other Rho GTPase subfamily members is an important regulator of oligodendrocyte morphology (Mi *et al.*, [@B46]; Thurnherr *et al.*, [@B72]). Over-expression of dominant-negative RhoA causes hyperextension of oligodendrocyte processes (Wolf *et al.*, [@B82]) while a reduction of active RhoA-GTP is necessary for successful oligodendrocyte differentiation (Liang *et al.*, [@B42]). To assess activation of RhoA in OPCs cultured on MPE and control substrates for 24 h in differentiation medium we performed a RhoA-GTP-pull down assay followed by Western blot for RhoA. Our data show that the presence of myelin inhibitors induces an increase of GTP bound RhoA (*n* = 3; *t*-test: *P* = 0.0113; [Fig. 2](#F2){ref-type="fig"}C and D).

To assess the functional role of RhoA in mediating inhibitory effects of MAI to OPC differentiation we transfected OPCs with siRNA specifically directed against RhoA. Cells were transfected with high efficiency (\>95%). This induced a marked down-regulation of the expression of RhoA as assessed by Western blot. The reduction of RhoA powerfully triggered OPC differentiation in the presence of MPE ([Fig. 5](#F5){ref-type="fig"}; *n* = 3; mean increase = 233%; ANOVA: *P* \< 0.0001, Dunnett\'s post-test MPE versus siRNA: *P* \< 0.0001) confirming the importance of RhoA in mediating the inhibitory effects as well as indicating that these can be beneficially modulated by inhibiting RhoA signalling in OPCs.

Inhibition of ROCK-II induces differentiation of OPCs in the presence of myelin
-------------------------------------------------------------------------------

Rho kinases (ROCK) are important effector proteins of RhoA and phosphorylate a number of downstream molecules that regulate actin filaments (Riento and Ridley, [@B58]). Since ROCK-II is the isoform predominantly expressed in the CNS, we hypothesized its participation in transducing myelin derived inhibitory signals in OPCs. We first confirmed ROCK-II expression in OPCs by Western blot analysis and then examined its functional role by plating OPCs on MPE and adding different concentrations of the ROKα/ROCK II-inhibitor HA-1077 (Fasudil) to the differentiation medium ([Fig. 3](#F3){ref-type="fig"}). Treatment with HA-1077 for 48 h resulted in a dramatic increase in the number of differentiating OPCs (*n* = 4; mean increase at 5 µM = 174%; ANOVA: *P* \< 0.0001, Dunnett\'s post tests MPE versus 5 and 10 µM: *P* \< 0.001). To exclude changes in cell survival we conducted TUNEL assays which showed no significant differences between OPCs plated on PLL and cells plated on MPE treated with HA-1077 ([Supplementary Fig. 1](http://brain.oxfordjournals.org/cgi/content/full/awn334/DC1)). Fig. 3(**A**) Immunoblot of OPC lysates demonstrates that differentiating OPCs express ROCK-II. (**B**) Inhibition of ROCK-II by culturing OPCs on MPE with Fasudil (HA-1077) results in a more than 160% increase of differentiating cells after 48 h culture in differentiation medium. (**C**) Whereas OPCs on MPE down-regulate O4 immunoreactivity. (**D**) O4 expression is largely restored by treatment with HA-1077 (scale bar = 30 µM).

Thus, we conclude that RhoA-ROCK signalling plays an important role in mediating myelin derived inhibitory effects in differentiating OPCs that can be beneficially modulated by the use of pharmacological inhibitors and siRNA-mediated gene silencing.

Myelin inhibitors retain Myristoylated, alanine-rich C-kinase substrate within the cytosolic compartment
--------------------------------------------------------------------------------------------------------

PKC has also been implicated in OPC differentiation since PKC activation mimicked by the phorbol ester PMA inhibits OPC differentiation (Baron *et al.*, [@B9]) while at late stages of OPC differentiation, PKC may also facilitate process extension and expression of myelin proteins (Althaus *et al.*, [@B3]; Yong *et al.*, [@B87]; Asotra and Macklin, [@B6]; Stariha and Kim, [@B66]). Myristoylated, alanine-rich C-kinase substrate (MARCKS) is a substrate of PKC that has been used as an indirect marker for PKC activation in OPCs (Baron *et al.*, [@B10]). Inhibitory PKC mediated signalling is associated with phosphorylation and membrane-to-cytosol translocation of MARCKS (Baron *et al.*, [@B10]) and may cause disorganization of the cytoskeleton and redistribution of actin filaments (Baron *et al.*, [@B9], [@B10]). MARCKS has been implicated in several cellular processes such as secretion, phagocytosis, cell motility, membrane traffic, growth suppression and regulation of the cell cycle as well as OPC differentiation (Baron *et al.*, [@B9], [@B10]; Arbuzova *et al.*, [@B5]). Phosphorylated MARCKS is translocated from the plasma membrane to the cytosol (Wang *et al.*, [@B78]; Thelen *et al.*, [@B71]; Byers *et al.*, [@B12]; Allen and Aderem, [@B2]). To detect changes in the intracellular distribution of MARCKS OPCs plated on MPE and control-PLL stained for A2B5 and MARCKS were compared using a laser scanning microscope ([Fig. 4](#F4){ref-type="fig"}A--F). In differentiating OPCs MARCKS was distributed to the cell membrane whereas in OPCs in which differentiation was inhibited by the presence of MPE a clear cytosolic presence of MARCKS was detected supporting the notion that PKC is activated by myelin and that myelin inhibitors modulate cytoskeletal dynamics by MARCKS. Fig. 4(**A--F**) MARCKS is a down-stream effector of PKC. While in control cells MARCKS expression is associated with the cell membrane, myelin inhibitors lead to a cytoplasmatic MARCKS presence. (**G--N**) Inhibition of PKC signaling in OPCs on MPE with BIM (**G--J**; max. mean increase 169%) or Gö6976 (**K--N**; max. mean increase 269%) strongly induces OPC differentiation after 48 h incubation in differentiation medium. (Scalebar: in **A--C**: 15.9 µm, in **D--F**: 14.6 µm in **H--J**, **L--N**: 30 µm).

PKC inhibitors promote OPC differentiation in the presence of myelin inhibitors
-------------------------------------------------------------------------------

In order to test whether inhibition of PKC signalling is able to modulate the myelin-mediated differentiation block OPCs plated on myelin were treated with the two selective PKC inhibitors, BIM (Bisindolylmaleimide IX, Methasulfonate Salt) and Gö6976. We found that treatment with BIM (*n* = 4; mean increase at 6.25 nM = 169%; ANOVA: *P* \< 0.0001, Dunnett\'s post tests MPE versus 6.25 nM: *P* \< 0.001; 12.5 nM: *P* \< 0.05) and even more so with Gö6976 (*n* = 3; mean increase at 50 nM = 267%; ANOVA: *P* \< 0.0001, Dunnett\'s post-test MPE versus 25 nM: *P* \< 0.05; 50 nM: *P* \< 0.001) was able to stimulate OPC differentiation in the presence of myelin ([Fig. 4](#F4){ref-type="fig"}G--N). TUNEL assays showed no differences in the rate of apoptosis between control cells and OPCs plated on myelin treated with Bim or Gö-6976 ([Supplementary Fig. 1](http://brain.oxfordjournals.org/cgi/content/full/awn334/DC1)). As the use of pharmacological inhibitors entails the risk of regulating cascades other than the targeted, we used siRNA to down-regulate PKC-α expression in OPCs plated on myelin ([Fig. 5](#F5){ref-type="fig"}). SiRNA-mediated silencing of PKC-α was successful and cells transfected displayed a marked decrease of PKC-α at protein level. The reduction of PKC-α potently induced OPC differentiation on MPE confirming the validity of the pharmacological approach (*n* = 3; mean increase = 232%; ANOVA: *P* \< 0.0001, Dunnett\'s post test MPE versus siRNA: *P* \< 0.0001) ([Fig. 5](#F5){ref-type="fig"}). Fig. 5(**A** and **B**) Transfection efficiency of OPCs was monitored by transfecting cells with RNAi (cy-3) and assessing the proportion of cy-3-labelled cells after 48 h in differentiation medium (*n* = 3); in all experiments \>95% of the cells were cy-3 positive. Immunoblots of OPC lysates after transfection with (**C**) RNAi for RhoA as well as (**D**) RNAi for PKC-α demonstrate downregulation of RhoA or PKC-α on protein level after 48 h. (**D**) Silencing of RhoA or PKC-α results in a significant increase of O4 positive cells when cultured for 48 h on MPE. (**F**) Whereas transfection with control RNAi (RNAi(scrambled, scr)) was not able to restore O4-immuroreactivity of OPCs on MPE (**G** and **H**) gene silencing induced a strong increase in the number of differentiating cells (scalebar = 30 µM).

Blocking both ROCK-II and PKC further promotes OPC differentiation
------------------------------------------------------------------

We next investigated whether ROCK-II and PKC transduce inhibitory signals via common or separate mechanisms and whether blocking both pathways at the same time could further promote OPC differentiation in the presence of myelin inhibitors. Treatment with Fasudil and Gö6976 simultaneously induced a further increase of the percentage of differentiating OPCs ([Fig. 6](#F6){ref-type="fig"}; *t*-test: HA-1077 versus co-incubation: *P* = 0.0009; Gö6976 versus co-incubation: *P* = 0.0288). Furthermore, the treatment of OPCs on MPE with the inhibitors was able to reverse the effects of myelin on OPC morphology and resulted in the presence of more mature phenotypes (stages III and IV, [Fig. 6](#F6){ref-type="fig"}; ANOVA of early stages (I/II) in PLL, MPE, and co-treatment *P* = 0.0027; Dunn post-test: MPE versus co-treatment *P* \< 0.01). MPE may not include all inhibitory factors present in crude myelin preparations. To ensure that the beneficial treatment effects were not restricted to substrates prepared with MPE we incubated OPCs plated on crude myelin preparations with HA-1077, Gö6976, or a combination of both. This resulted in a similar induction of OPC differentiation in the presence of myelin inhibitors (data not shown). Taken together our findings suggest that the inhibitory effects of myelin molecules are mediated by at least two independent pathways. Furthermore, blocking both pathways simultaneously may provide an even more potent strategy to improve OPC differentiation in an *in vivo* setting. Fig. 6(**A--C**) Blocking PKC and ROCK-II simultaneously in OPCs plated on myelin by co-incubation with HA-1077 and Gö6976 induces an additional increase in the percentage of O4-positive cells as compared to single treatment after incubation in differentiation medium for 48 h. (**B**) While MPE induces down-regulation of O4 immunoreactivity in OPCs (**C**: the same cells stained for A2B5), (**D**) O4 expression is restored after treatment with the pharmacological inhibitors. (**E--G**) The presence of MPE is associated with a reduction of the complexity of OPC processes and earlier morphological stages as compared to OPCs plated on control substrate. (**H**) Treatment with HA-1077 and Gö6976 restores the presence of more mature phenotypes (scalebar = 30 µM).

Discussion
==========

Axonal integrity is tightly coupled with myelin function as subtle changes in the molecular composition can result in mid- to long term axonal degeneration under otherwise physiological conditions (Griffiths *et al.*, [@B27]; Garbern *et al.*, [@B24]; Lappe-Siefke *et al.*, [@B40]; Nave and Trapp, [@B48]). The trophic function of myelin sheaths is also very likely to be of significance for maintaining axonal integrity in both acute and chronic CNS pathology, a situation in which denuded axons may be more prone to injury or degeneration than axons bearing functionally intact myelin sheaths. Thus increasing efforts have been placed in the development of strategies by which remyelination may be enhanced therapeutically (Dubois-Dalcq *et al.*, [@B19]). Although much is known about the biology of OPCs attempts to stimulate remyelination *in vivo* by increasing or modulating the expression proliferation or differentiation inducing factors have not been universally successful, especially when older adult animals are used in which myelin debris clearance is poor and remyelination inefficient (Shields *et al.*, [@B63]; O'Leary *et al.*, [@B52]; Sim *et al.*, [@B64]; Penderis *et al.*, [@B56]; Ibanez *et al.*, [@B30]; Woodruff *et al.*, [@B86]). The presence of inhibitory molecules in myelin debris generated as a consequence of oligodendrocyte degeneration may in part provide an explanation for the so far generally frustrating failure of these different strategies (Kotter *et al.*, [@B36]).

The key aim of our study was to examine the mechanisms that control the myelin mediated inhibition of OPC differentiation. The myelin molecules blocking OPC differentiation remain unknown. However, it is a plausible hypothesis that these molecules expressed on mature oligodendrocytes provide a feed-back inhibition for early (A2B5+) precursor cells. Under normal physiological situations this feed-back system may serve to prevent inappropriate differentiation of OPCs in normal adult white matter (Robinson and Miller, [@B59]), while in development one might speculate that signalling from mature oligodendrocytes to early precursors may play a functional role in regulating OPC differentiation. The situation following demyelination entails profound environmental changes as large amounts of degenerated myelin can accumulate within lesions. In experimental models this is efficiently cleared by macrophages of microglial and monocytic origin (Kotter *et al.*, [@B37], [@B38]). However, it is conceivable that if clearance of myelin debris is disturbed by alterations of the inflammatory response the presence of myelin debris can persist and thus for a prolonged period inhibit myelin repair. Recent studies suggest that remyelination requires the signalling environment provided by an acute inflammatory response (Mason *et al.*, [@B44]; Foote and Blakemore, [@B21]; Kotter *et al.*, [@B38]; Setzu *et al.*, [@B62]). Therefore, it could be speculated that a situation may occur in which the initial inclination OPCs to differentiate is inhibited by the presence of myelin and turns into reluctance as the expression of signalling molecules required to activate OPCs diminishes.

The cascades that we found to be modulated by the presence of myelin inhibitors are similar to the ones that regulate the inhibition of axon growth via NogoR and Lingo-1 signalling (Lee *et al.*, [@B41]; Mi *et al.*, [@B46]). However, there is no evidence that NogoR is expressed by OPCs and we ourselves were not able to detect NogoR expression in our cultures. While immunocytochemistry for Lingo-1 is inconclusive we found evidence of Lingo-1 mRNA in cultured OPCs (unpublished data). Furthermore, we have not seen evidence of an inhibitory effect of any of the classical myelin inhibitors of axon growth on OPC differentiation (Syed *et al.*, [@B68]). Thus the molecular substrate present in myelin mediating the inhibitory effects remains unknown.

In this study, we developed a biochemical and proteomic protocol to identify potential candidates responsible for the myelin differentiation block. With the criteria we applied this resulted in a list of 137 myelin proteins---18 of which were previously identified using a proteomic approach. The detection of so many previously unidentified proteins in myelin can be explained in part by the biochemical separation process we developed, which removes many of the most abundant proteins. On the other hand, we applied a gel-based separation technique that is specifically tailored for the study of membrane-bound proteins that has not been previously used for the analysis of the myelin proteome. To identify the myelin protein(s) responsible for the inhibition of OPC differentiation further separation steps may be helpful. However, stringent data assessment may help to narrow down the list of potential candidates. Apart from providing a list of potential candidates our data illustrates the complexity of myelin and will provide a reference for further studies of the biology of myelin membranes.

Our results provide a model of how myelin exerts inhibitory effects on OPC differentiation. In inhibiting RhoA-ROCK and PKC(-α) signalling we have identified pharmacological targets by which OPC differentiation can be powerfully stimulated in the context of myelin inhibitors.

Fasudil is currently evaluated in a clinical setting for treatment of vasospasm as well as angina pectoris in humans (Vicari *et al.*, [@B76]). Similarly, a number of clinical studies investigate the effects of PKC inhibitors in cancer (Mackay and Twelves, [@B43]). While it has to be expected that not all inhibitors can pass the brain blood barrier, a number of PKC inhibitors (e.g. Tamoxifen, Calphostin-C, HA-1004 and Ro 32-0432) (Gozal *et al.*, [@B26]; Cerezo *et al.*, [@B14]; Zarate *et al.*, [@B88]) as well as Rho-cascade inhibitors (e.g. Fasudil) are able to cross the brain blood barrier (Satoh *et al.*, [@B61]).

PKC and ROCK inhibition have shown to exert stimulating effects on neurite outgrowth in the presence of myelin inhibitors, and thus synergistic effects with respect to neural repair could be expected (Sivasankaran *et al.*, [@B65]). As far as effects on other cell types are concerned, inhibition of PKC in microglia is associated with e.g. downregulation of MHC-II (Nikodemova *et al.*, [@B49]), a reduction of proinflammatory cytokine, iNOS (Kang *et al.*, [@B33]; Min *et al.*, [@B47]), and TNF-α release (Jeohn *et al.*, [@B31]) in response to various inflammatory modulators including LPS, ganglioside and IFNγ suggesting a reduction of proinflammatory activity in microglia. On the other hand, it has been reported that PKC inhibition lead to reduced CR3/Mac-1 and SRAI/II mediated myelin phagocytosis (Cohen *et al.*, [@B17]) which may be relevant to myelin repair although the mechanisms we report aim at neutralizing the effects of MAI on OPC differentiation.

Astrocytes react upon PKC inhibition by e.g. decreased activation of ATP-mediated glutamate outwards channels (Rudkouskaya *et al.*, [@B60]) and TGFb1 production (Wang *et al.*, [@B77]), furthermore, the response to LPA is altered by a reduced proproliferative intracellular Ca2+ increase (Keller *et al.*, [@B35]) and NGF secretion (Furukawa *et al.*, [@B23]). It is difficult to interpret these findings in the light of remyelination as little is known about the molecular events in astrocytes during myelin repair. However, it seems unlikely that the effects of PKC inhibition on astrocytes reported will negatively impact remyelination.

Under the influence of Fasudil rat astrocytes transform *in vitro* into process bearing cells (Abe and Misawa, [@B1]) which can be explained by direct effects of the Rho-cascade on the cytoskeleton, on the other hand there are no data available how changes in astrocyte processes impact myelin repair.

Finally, little is known of how microglia react to inhibition of the Rho-cascade. A recent paper suggests that inhibition of RhoA by C3 induces NO and proinflammatory cytokine release, however, this is independent of ROCK signalling and was instead found to be under the control of NFkappaB suggesting that targeting down-stream signalling events may circumvent problems that may arise as a consequence of microglia activation (Hoffmann *et al.*, [@B28]).

Our data suggest that inhibiting PKC and/or Rho-signalling would be beneficial either acutely following demyelination, where exposure to myelin debris that has yet to be cleared might critically interrupt the initiation of remyelination resulting in its long term failure or in chronic disease where OPCs remain exposed to a differentiation-inhibitory environment. The data in the current study paves the way for subsequent testing of pharmacological interventions in animal models and further clinical evaluation if the outcome were to be successful.
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MARCKS

:   Myristoylated, alanine-rich C-kinase substrate

MBP

:   myelin basic protein

MPEs

:   myelin protein extracts

OPC

:   oligodendrocyte precursor cells

PKC

:   protein kinase C

PLL

:   polylysine

3DE

:   Three dimensional electrophoresis

[^1]: \*These authors contributed equally to this work.

[^2]: a NCBI accession number (Acc. No.) is referred in website (<http://www.ncbi.nlm.nih.gov/sites/entrez>). b Theoretical number of transmembrane domain (TMD) was calculated in website (<http://www.expasy.org>).
